CD133 negatively regulates tumorigenicity via AKT pathway in synovial sarcoma

Cancer Invest. 2012 Jun;30(5):390-7. doi: 10.3109/07357907.2012.672607.

Abstract

Synovial sarcoma (SS) is an aggressive tumor that accounts for almost 10% of all soft tissue sarcomas. In this study, we found the expression of CD133 in human SS specimens, thus, we focused on the function of CD133 in SS. Separation of the CD133-positive and -negative subpopulations in SS cell lines clarified that the CD133-negative subpopulation exhibited enhanced growth and hyperphosphorylation of AKT. Treatment of Akt inhibitor suppressed the cell growth of CD133-negative subpopulation to the levels of CD133-positive cells. These results suggest that CD133 has negative effect on the growth of cells through AKT-dependent signalling pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AC133 Antigen
  • Animals
  • Antigens, CD / analysis
  • Antigens, CD / physiology*
  • Cell Line, Tumor
  • Female
  • Glycoproteins / analysis
  • Glycoproteins / physiology*
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Peptides / analysis
  • Peptides / physiology*
  • Proto-Oncogene Proteins c-akt / physiology*
  • Sarcoma, Synovial / etiology*
  • Signal Transduction / physiology*

Substances

  • AC133 Antigen
  • Antigens, CD
  • Glycoproteins
  • PROM1 protein, human
  • Peptides
  • Prom1 protein, mouse
  • Proto-Oncogene Proteins c-akt